Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Melanoma 17Carcinoma, Renal Cell 7Multiple Myeloma 4Recurrence 3Leukemia 3Carcinoma, Hepatocellular 3Triple Negative Breast Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lymphoma 2Breast Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Small Cell Lung Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Mycosis Fungoides 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lung Neoplasms 1Liver Neoplasms 1Liver Cirrhosis 1Leukemia-Lymphoma, Adult T-Cell 1Kidney Neoplasms 1Hepatitis C, Chronic 1Hepatitis C 1

Interventions

Trastuzumab 351Paclitaxel 334Cyclophosphamide 315Docetaxel 292Capecitabine 181Doxorubicin 180Letrozole 165Tamoxifen 145Bevacizumab 124Fulvestrant 118Carboplatin 118exemestane 111Lapatinib 111Anastrozole 111Radiotherapy 105Epirubicin 104Gemcitabine 97palbociclib 83Exercise 78Vinorelbine 77Fluorouracil 77Surveys and Questionnaires 71pertuzumab 68Filgrastim 64Albumin-Bound Paclitaxel 64Magnetic Resonance Spectroscopy 56eribulin 55Everolimus 52Blood Specimen Collection 51Zoledronic Acid 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Breast Neoplasms × Introns × Clear all
NCT04081389 2023-09-11

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Roswell Park Cancer Institute

Phase 1 Completed
9 enrolled 17 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03066947 2021-01-29

SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer

BriaCell Therapeutics Corporation

Phase 1/2 Completed
24 enrolled 12 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡